Enzyme By Design
Biotechnology, 2242 W Harrison St Ste 201-39, Chicago, Illinois, 60612, United States, 1-10 Employees
Phone Number: 13*********
Who is ENZYME BY DESIGN
Enzyme by Design (EbD) is a preclinical stage startup focused on designing and developing oncology biologics that are highly effective at exploiting weaknesses in cancers and eradicating ...
Read More
-
Headquarters: 2242 W Harrison St Ste 201-39, Chicago, Illinois, 60612, United States
-
Date Founded: 2017
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 7372
|
NAICS Code: 513210 |
Show More
Does something look wrong? Fix it. | View contact records from ENZYME BY DESIGN
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Enzyme by Design
Answer: Enzyme by Design's headquarters are located at 2242 W Harrison St Ste 201-39, Chicago, Illinois, 60612, United States
Answer: Enzyme by Design's phone number is 13*********
Answer: Enzyme by Design's official website is https://enzymebydesign.com
Answer: Enzyme by Design's revenue is $1 Million to $5 Million
Answer: Enzyme by Design's SIC: 7372
Answer: Enzyme by Design's NAICS: 513210
Answer: Enzyme by Design has 1-10 employees
Answer: Enzyme by Design is in Biotechnology
Answer: Enzyme by Design contact info: Phone number: 13********* Website: https://enzymebydesign.com
Answer: Enzyme by Design (EbD) is a preclinical stage startup focused on designing and developing oncology biologics that are highly effective at exploiting weaknesses in cancers and eradicating tumor cells but with a clear focus on patient safety and reducing side effects. In this way, we can both treat the disease and improve patient quality of life and outcomes. We have used our core expertise of protein engineering to create protein molecules that target the most common pediatric cancer as well as infamously difficult to treat cancers like acute myeloid leukemia and the solid tumors pancreatic, liver, and ovarian cancers. Utilizing well-known drug mechanisms of action and patient genomic and epigenetic markers will guide our clinical strategy as we move forward to make sure that only patients likely to benefit greatly from our biologics will be receiving them. The time is now for better cancer treatment options.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month